Mind Cure Health (CSE: MCUR) has reached a milestone, with the company this morning announcing its translational research program that will initially focus on the compounds of psilocybin, ibogaine, and ketamine. Research into the compounds is said to be largely focused on the treatment of physical and psychological pain and related mental health illnesses.
Translational research in layman terms is multidisciplinary and involves applying lab research and preclinical studies to developing clinical trials and studies in humans. Unlike applied science, translation research is said to be solely focused on improving health outcomes.
The program is intended to enable Mind Cure to investigate the compounds of psilocybin, ketamine and ibogaine for use in pharmaceuticals. All three are said to have demonstrated safety profiles that have a proven efficacy, but the compounds have yet to be optimized for medical use. The research will be focused on “delivering validation of commercially viable medicines, methods and tools to address numerous priorities in treating mental health.”
“Despite social stigmas, many classical psychedelics have safely demonstrated profound therapeutic effectiveness with alleviating all forms of pain associated with neurological trauma and chronic diseases. We begin our research with tremendous promise for new medicines that share structural similarities with improved receptor targeting, dosing, and therapeutic profiles.”
Dr. Ryan Hartwell
The company is currently focused on executing on this approach of research into psychedelics as a means of expediting research and development programs. Further, the program is said to holistically account for the lasting effects on quality of life and clinical outcomes in patients as a result of the mixed effects of physical and psychological pain.
Mind Cure Health last traded at $0.65 on the CSE.
FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
